Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2023; 13(13):4526-4558. doi:10.7150/thno.87266 This issue Cite

Review

Organ-on-a-chip meets artificial intelligence in drug evaluation

Shiwen Deng1, Caifeng Li1,4, Junxian Cao1, Zhao Cui1,2, Jiang Du3, Zheng Fu4✉, Hongjun Yang1,4✉, Peng Chen1,3,4✉

1. Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
3. Yunnan Biovalley Pharmaceutical Co., Ltd, Kunming 650503, China.
4. Robot Intelligent Laboratory of Traditional Chinese Medicine, Experimental Research Center, China Academy of Chinese Medical Sciences & MEGAROBO, Beijing 100700, China.

✉ Corresponding author: Peng Chen (chenpengac.cn); Hongjun Yang (hongjun0420sina.com); Zheng Fu (fuzhengtech).

Citation:
Deng S, Li C, Cao J, Cui Z, Du J, Fu Z, Yang H, Chen P. Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics 2023; 13(13):4526-4558. doi:10.7150/thno.87266. https://www.thno.org/v13p4526.htm
Other styles

File import instruction

Abstract

Graphic abstract

Drug evaluation has always been an important area of research in the pharmaceutical industry. However, animal welfare protection and other shortcomings of traditional drug development models pose obstacles and challenges to drug evaluation. Organ-on-a-chip (OoC) technology, which simulates human organs on a chip of the physiological environment and functionality, and with high fidelity reproduction organ-level of physiology or pathophysiology, exhibits great promise for innovating the drug development pipeline. Meanwhile, the advancement in artificial intelligence (AI) provides more improvements for the design and data processing of OoCs. Here, we review the current progress that has been made to generate OoC platforms, and how human single and multi-OoCs have been used in applications, including drug testing, disease modeling, and personalized medicine. Moreover, we discuss issues facing the field, such as large data processing and reproducibility, and point to the integration of OoCs and AI in data analysis and automation, which is of great benefit in future drug evaluation. Finally, we look forward to the opportunities and challenges faced by the coupling of OoCs and AI. In summary, advancements in OoCs development, and future combinations with AI, will eventually break the current state of drug evaluation.

Keywords: Organ-on-a-chip, Microfluidics, Drug evaluation, Artificial intelligence, In vitro model.

Citation styles

APA
Deng, S., Li, C., Cao, J., Cui, Z., Du, J., Fu, Z., Yang, H., Chen, P. (2023). Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics, 13(13), 4526-4558. https://doi.org/10.7150/thno.87266.

ACS
Deng, S.; Li, C.; Cao, J.; Cui, Z.; Du, J.; Fu, Z.; Yang, H.; Chen, P. Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics 2023, 13 (13), 4526-4558. DOI: 10.7150/thno.87266.

NLM
Deng S, Li C, Cao J, Cui Z, Du J, Fu Z, Yang H, Chen P. Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics 2023; 13(13):4526-4558. doi:10.7150/thno.87266. https://www.thno.org/v13p4526.htm

CSE
Deng S, Li C, Cao J, Cui Z, Du J, Fu Z, Yang H, Chen P. 2023. Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics. 13(13):4526-4558.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use